Silibinin inhibits tumor growth in a murine orthotopic hepatocarcinoma model and activates the TRAIL apoptotic signaling pathway

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2455-2462

  Bousserouel, Souad ^a   Bour, Gaetan ^b   Kauntz, Henriette ^a   Gossé, Francine ^a   Marescaux, Jacques ^b   Raul, Francis ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Research Institute Against Digestive Cancer European Institute of TeleSurgery   (France)

Author keywords

Apoptosis; Caspases; Death receptor; Inflammation; Liver cancer; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; DEATH RECEPTOR 5; GELATINASE B; INTERLEUKIN 1BETA; MATRILYSIN; SILIBININ; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; DRUG SCREENING; ENZYME ACTIVATION; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT OUTCOME; UPREGULATION;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; SILYMARIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84865683855     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide. In: IARC CancerBase No. 10.Lyon, France: International Agency for Research on Cancer, 2010.
2. Seeff LB and Hoofnagle JH: Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene 25: 3771-3777, 2006. (Pubitemid 43980472)
3. Schafer DF and Sorrell MF: Hepatocellular carcinoma. Lancet 353: 1253-1257, 1999. (Pubitemid 29168472)
4. Avila MA, Berasain C, Sangro B and Prieto J: New therapies for hepatocellular carcinoma. Oncogene 25: 3866-3884. 2006. (Pubitemid 43980482)
5. Kojima S, Okuno M, Matsushima-Nishiwaki R, Friedman SL and Moriwaki H: Acyclic retinoid in the chemoprevention of hepatocellular carcinoma. Int J Oncol 24: 797-805, 2004.
6. Yuan S, Zhang X, Lu L, Xu C, Yang W and Ding J: Anticancer activity of methoxymorpholinyl doxorubicin (P NU 152243) on human hepatocellular carcinoma. Anticancer Drugs 15: 641-646, 2004. (Pubitemid 38932335)
7. Chun E and Lee KY: BCL-2 and BCL-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 315: 771-779, 2004. (Pubitemid 38229409)
8. Chao Y, Chan WK, Birkhofer MJ, Hu OY, Wang SS, Huang YS, Liu M, Whang-Peng J, Chi KH, Lui WY and Lee SD: Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 78: 34-39, 1998. (Pubitemid 28276766)
9. O'Reilly EM, Stuart KE, Sanz-Altamira PM, Schwartz GK, Steger CM, Raeburn L, Kemeny NE, Kelsen DP and Saltz LB: A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 91: 101-105, 2001 (Pubitemid 32052619)
10. Su SJ, Chow NH, Kung ML, Hung TC and Chang KL: Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, BCL-2 and BCL- down-regulation, and CDC2 kinase activity. Nutr Cancer 45: 113-123, 2003.
11. Kao ST, Yeh CC, Hsieh CC, Yang MD, Lee MR, Liu HS and Lin JG: The Chinese medicine Bu-Zhong-Yi-Qi-Tang inhibited proliferation of hepatoma cell lines by inducing apoptosis via G0/G1 arrest. Life Sci 69: 1485-1496, 2001.
12. Luper S: A review of plants used in the treatment of liver disease: part 1. Altern Med Rev 3: 410-421, 1998.
13. Deep G and Agarwal R: Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther 6: 130-145, 2007. (Pubitemid 46871840)
14. Cheung CW, Taylor PJ, Kirkpatrick CM, Vesey DA, Gobe GC, Winterford C, Nicol DL and Johnson DW: Therapeutic value of orally administered silibinin in renal cell carcinoma: manipulation of insulin-like growth factor binding protein-3 levels. BJU Int 100: 438-444, 2007. (Pubitemid 47036591)
15. Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD, Malkinson AM and Agarwal R: Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst 98: 846-855, 2006. (Pubitemid 43923441)
16. Kauntz H, Bousserouel S, Gossé F and Raul F: Silibinin triggers apoptotic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived metastatic cells. Apoptosis 16: 1042-1053, 2011.
17. Kauntz H, Bousserouel S, Gossé F, Marescaux J and Raul F: Silibinin, a natural flavonoid, modulates the early expression of chemopreventive biomarkers in a preclinical model of colon carcinogenesis. Int J Oncol in press, 2012.
18. Leenders MWH, Nijkamp MW and Borel Rinkes IHM: Mouse models in liver cancer research: A review of current literature. World J Gastroenterol 14: 6915-6923, 2008.
19. Raul F, Gossé F, Osswald AB, Bouhadjar M, Foltzer-Jourdainne C, Marescaux J and Soler L: Follow-up of tumor development in the colon of living rats and implications for chemoprevention trials: Assessment of aspirin-difluoromethylornithine combination. Int J Oncol 31: 89-95, 2007.
20. Aprahamian M, Bour G, Akladios CY, Fylaktakidou K, Greferath R, Soler L, Marescaux J, Egly JM, Lehn JM and Nicolau C: Myo-InositolTrisPyroPhosphate treatment leads to HIF-1á suppression and eradication of early hepatoma tumors in rats. Chembiochem 12: 777-83, 2011.
21. Soler L, Delingette H, Malandain G, Montagnat J, Ayache N, Koehl C, Dourthe O, Malassagne B, Smith M, Mutter D and Marescaux J: Fully automatic anatomical, pathological, and functional segmentation from CT scans for hepatic surgery. Comput Aided Surg 6: 131-142, 2001. (Pubitemid 33111133)
22. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
23. Riccardi C and Nicoletti I: Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 1: 1458-1461, 2006.
24. Herr I, Schemmer P and Buchler MW: On the TRAIL to therapeutic intervention in liver disease. Hepatology 46: 266-274, 2007. (Pubitemid 47171943)
25. Russo M, Mupo A, Spagnuolo C and Russo GL: Exploring death receptor pathways as selective targets in cancer therapy. Biochem Pharmacol 80: 674-682, 2010.
26. Hirankarn N, Kimkong I, Kummee P, Tangkijvanich P and Poovorawan Y: Interleukin-1beta gene polymorphism associated with hepatocellular carcinoma in hepatitis B virus infection. World J Gastroenterol 12: 776-779, 2006. (Pubitemid 43380763)
27. Yang Y, Luo C, Feng R and Bi S: The TNF-α, IL-1β and IL-39 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 137: 947-952, 2011.
28. Altadill A, Rodríguez M, González LO, Junquera S, Corte MD, González-Dieguez ML, Linares A, Barbón E, Fresno-Forcelledo M, Rodrigo L and Vizoso FJ: Liver expression of matrix metalloproteases and their inhibitors in hepatocellular carcinoma. Dig Liver Dis 41: 740-748, 2009.
29. Willmann JK, van Bruggen N, Dinkelborg LM and Gambhir SS: Molecular imaging in drug development. Nat Rev Drug Discov 7: 591-607, 2008. (Pubitemid 351927724)
30. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 15: 513-520, 2009.
31. Mace TA, Yamane N, Cheng J, Hylander BL and Repasky EA: The potential of the tumor microenvironment to influence APO2L/TRAIL induced apoptosis. Immunol Invest 35: 279-296, 2006. (Pubitemid 44266777)
32. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002. (Pubitemid 36019639)
33. Bhowmick NA, Neilson EG and Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337. 2004. (Pubitemid 39551661)
34. Johansson N, Ahonen M and Kahari VM: Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci 57: 5-15, 2000. (Pubitemid 30105326)
35. Nyormoi O, Mills L and Bar-Eli M: An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ 10: 558-569, 2003. (Pubitemid 36656645)
36. Friedl P and Wolf K: Tumor-cell invasion and migration: Diversity and escape mechanisms. Nat Rev Cancer 3: 362-374, 2003. (Pubitemid 37328856)
37. Jeong WI and Gao B: Innate immunity and alcoholic liver fibrosis. J Gastroenterol Hepatol 23(Suppl 1): S112-S118, 2008.
38. Blankenstein T: The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 17: 180-186, 2005.